BPC-157: What the Published Evidence Actually Shows

BPC-157 is often called a healing peptide, yet nearly everything known about it comes from rats, mice and cell culture, much of it from one laboratory. Here is what had been published by October 2026, and how much weight it can bear.

What BPC-157 is, and who studies it

In 1993 Predrag Sikiric's group at the University of Zagreb described a gastric juice protein of about 40,000 daltons, named BPC (body protection compound), and a 15-amino-acid fragment, BPC 157, that they considered essential for its activity (Sikiric et al., 1993). Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (Staresinic et al., 2003). In the early 2000s the Croatian drug company Pliva took it into trials for inflammatory bowel disease as PL 14736.

Who produced the evidence matters. In a PubMed search we ran on 2 October 2026, 175 of 232 records that mention BPC-157 under any of its names, about three in four, list Sikiric as an author. Other groups, notably Chang Gung University in Taiwan and a military medical university in Xi'an, China, have added cell, pharmacokinetic and toxicology work, but few have repeated the key injury models, and reviewers now ask for independent, blinded replication (Demirtaş, 2026).

The animal and cell evidence, tissue by tissue

The model is named in each case.

• Gastrointestinal. In rats, BPC-157 reduced stomach and small-intestine lesions caused by non-steroidal anti-inflammatory drugs (Sikiric et al., 1997), and the FDA's 2026 review summarises further rat studies reporting protection against colonic fistulas and liver lesions. An unaffiliated Nanjing group found it reduced the return of healed stomach ulcers in rats given clopidogrel, an effect weakened when nitric oxide production was blocked (Wu et al., 2020).
• Tendon and ligament. In rats with a transected Achilles tendon it improved load to failure, function and tissue structure over 14 days (Staresinic et al., 2003), and it improved healing of a cut knee ligament over 90 days (Cerovecki et al., 2010). In an independent 2026 study of 32 rats with repaired Achilles tendons, the BPC-157 group beat controls on average but not significantly on strength or overall tissue scores, while the TB-500 group did (Biçer et al., 2026; see our BPC-157 vs TB-500 comparison).
• Muscle. After complete transection of the quadriceps in rats, it improved load to failure, walking and muscle fibre regeneration over 72 days (Staresinic et al., 2006). Rat studies of hind-limb ischaemia and reperfusion report less muscle damage (reviewed by Demirtaş, 2026).
• Nervous system. In mice with weight-drop brain injury it reduced bleeding, brain swelling and early deaths over 24 hours (Tudor et al., 2010), and rats with spinal cord compression regained more tail motor function and lost fewer nerve fibres over a year (Perovic et al., 2019). Both studies come from Zagreb.
• Blood vessels. In Taiwan it increased vessel growth in chick embryo membranes and human endothelial cell assays, and sped the return of blood flow in rats with an ischaemic hind limb (Hsieh et al., 2017). It relaxed isolated rat aorta through the vessel lining and nitric oxide (Hsieh et al., 2020), and a 2026 Turkish study saw similar relaxation in human artery rings left over from bypass surgery, tested in an organ bath rather than in people (Yildirim et al., 2026).

Such consistency deserves scrutiny. Several Zagreb studies report benefit at amounts a thousand-fold apart (Sikiric et al., 1997; Cerovecki et al., 2010), and the FDA's reviewers noted that no relationship between amount and effect has been established for the gut and liver findings. A critical review of the rodent ischaemia-reperfusion work found short observation periods, single-treatment designs and incompletely characterised risk of bias, and judged BPC-157 a hypothesis-generating candidate, not an established therapy (Demirtaş, 2026).

What the reviews conclude

Reviews published since 2025, all by authors outside the Zagreb group, broadly agree.

• Vasireddi et al. (2025), a systematic review to June 2024, screened 544 records and included 36 studies: 35 preclinical and one clinical, the retrospective knee report below. It rated the evidence at levels IV and V and found no clinical safety data.
• McGuire et al. (2025) counted three small human pilot studies, none reporting adverse effects, and called BPC-157 investigational until well-designed trials are done.
• Mateescu et al. (2026), found only three uncontrolled pilot studies in people, none using a standardised pharmaceutical preparation, and argued that the main barrier is missing pharmaceutical science, not missing biological activity.
• Demirtaş (2026) called for blinded replication, studies of amount and timing, pharmacokinetic work, rigorous toxicology and, eventually, controlled human studies.

What human data exist

The FDA's May 2026 evaluation identified five published clinical studies (FDA briefing document):

• Two from the 2000s development programme, known only from meeting abstracts. In 24 healthy volunteers given it rectally, headache and flatulence were the commonest side effects and the peptide was mostly undetectable in blood. In a randomised, placebo-controlled Phase II trial in 53 people with mild to moderate ulcerative colitis, the confidence interval for the difference between groups crossed zero, and the FDA judged the data inadequate.
• A retrospective chart review at a Florida clinic: of 16 patients reached by phone, 11 of the 12 given BPC-157 alone into the knee reported significant pain relief, with no control group or standard outcome measure (Lee and Padgett, 2021).
• An uncontrolled pilot in 12 women with interstitial cystitis, treated once into the bladder wall: 10 reported complete symptom resolution on a questionnaire, and no adverse events were reported (Lee et al., 2024).
• An intravenous safety pilot in two previously exposed adults: no changes in routine blood tests and no side effects reported (Lee and Burgess, 2025).

The three recent reports share a lead author and private-clinic settings, and none had a control group. The FDA found no information to assess pharmacokinetics in humans. In rats and dogs the intact peptide's blood half-life is under 30 minutes, and it is broken down into small fragments and amino acids (He et al., 2022). The same Xi'an group found no serious toxicity in mice, rats, rabbits and dogs (Xu et al., 2020), but the FDA judged the available toxicology too limited to inform clinical safety. Its adverse event database held three reports to December 2025 (local redness and swelling, shortness of breath, and skin and gum darkening that recurred with a combined BPC-157 and TB-500 product), none confidently attributable to BPC-157.

On ClinicalTrials.gov (checked 2 October 2026), a 2015 Phase 1 study in Mexico has an unknown status (NCT02637284). The largest controlled study registered is a randomised, double-blind, placebo-controlled Phase 2 trial in acute hamstring strain, planned for 120 participants and recruiting in Shenzhen since February 2026 (NCT07437547). Neither has posted results.

Proposed mechanisms, and how strong the evidence is

• Angiogenesis through VEGFR2. In human endothelial cells it raised levels of VEGFR2, a receptor that drives vessel growth, promoted its uptake into the cell and activated the Akt-eNOS pathway; blocking that uptake cancelled its effect on tube formation (Hsieh et al., 2017).
• Nitric oxide. Best supported in isolated vessels: lining-dependent, nitric oxide-dependent relaxation of rat aorta with activation of Src, caveolin-1 and eNOS (Hsieh et al., 2020), and similar relaxation in human artery rings (Yildirim et al., 2026).
• Growth hormone receptor. In rat tendon cells it raised growth hormone receptor levels, and added growth hormone then increased proliferation, with JAK2 signalling activated (Chang et al., 2014); faster tendon cell outgrowth and migration, without faster division, have been linked to FAK-paxillin signalling (Chang et al., 2011). Both are cell culture results from one laboratory.
• A binding partner. A 2026 Xi'an study reported that BPC-157 binds FBXO22, a protein that marks others for breakdown, stabilising the transcription factor BACH1 and supporting endothelial cell growth (Zhang et al., 2026). We found no other PubMed record examining it.

Each pathway rests mainly on cultured cells or isolated tissue, usually from one laboratory, showing what BPC-157 can do in a dish rather than which effect matters in a living animal. In May 2026 the FDA's reviewers wrote that its molecular targets have not been identified and its mechanisms remain poorly understood. There is also a timing puzzle: the intact peptide lasts under 30 minutes in animal blood, yet reported effects last hours to days (Mateescu et al., 2026).

Regulatory status in October 2026

According to the FDA's May 2026 review, no product containing BPC-157 is approved in any country.

• Sport. WADA first named BPC-157 in its 2022 Prohibited List (WADA, 2021). The 2026 list, in force since 1 January 2026, still names it under S0, non-approved substances, which are prohibited at all times.
• United States. On 29 September 2023 the FDA placed BPC-157 in category 2 of its interim compounding policy, for bulk substances that may present significant safety risks (archived FDA page). The nominators later withdrew their nominations, and by 22 April 2026 the FDA's page listed BPC-157 among substances previously in category 2, keeping its warnings about immune reactions, impurities, and too little information to know whether it would harm people. The FDA's 503A categories list, updated 14 May 2026, places it in none of its three categories. The FDA then evaluated it on its own initiative for ulcerative colitis, and its reviewers concluded that the balance of criteria "weighs against" adding it to the list of substances US pharmacies may compound with. Its Pharmacy Compounding Advisory Committee was asked to vote on the question on 23 July 2026 (meeting page). The FDA says it will not issue a final determination until that input has been considered, and by 2 October 2026 it had published neither minutes nor a decision.

Open questions

• Replication. Do the healing results hold when unaffiliated laboratories repeat the key models with blinding and randomisation?
• Pharmacokinetics and targets. What reaches tissue in people, and will other laboratories confirm FBXO22?
• Safety. The FDA flagged immune reactions, impurities and aggregation, and the human studies were small and short.
• Identity. The FDA noted inconsistent naming, and that the free base and acetate salt are distinct substances.
• Effect in people. The hamstring trial is the first sizeable placebo-controlled test on the register, and it has not reported.

The bottom line

BPC-157 has a large, consistent and mostly single-source body of rodent evidence for tissue protection, plausible but unconfirmed mechanisms, and almost no controlled human data. Independent reviewers and the FDA's own scientists reach the same conclusion: it remains an investigational compound whose animal results have not been tested in rigorous human trials.

References

1. Biçer O, et al. (2026). Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Joint Diseases and Related Surgery. PubMed 42542926
2. Cerovecki T, et al. (2010). Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. Journal of Orthopaedic Research. PubMed 20225319
3. Chang CH, et al. (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology. PubMed 21030672
4. Chang CH, et al. (2014). Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. PubMed 25415472
5. Demirtaş H. (2026). BPC 157 in Rodent Ischemia-Reperfusion Injury: A Critical Review of Preclinical Evidence. International Journal of Molecular Sciences. PubMed 42794771
6. He L, et al. (2022). Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Frontiers in Pharmacology. PubMed 36588717
7. Hsieh MJ, et al. (2017). Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine. PubMed 27847966
8. Hsieh MJ, et al. (2020). Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway. Scientific Reports. PubMed 33051481
9. Lee E, Padgett B. (2021). Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Alternative Therapies in Health and Medicine. PubMed 34324435
10. Lee E, et al. (2024). Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Alternative Therapies in Health and Medicine. PubMed 39325560
11. Lee E, Burgess K. (2025). Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Alternative Therapies in Health and Medicine. PubMed 40131143
12. Mateescu DM, et al. (2026). BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers. Pharmaceutics. PubMed 42198317
13. McGuire FP, et al. (2025). Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Current Reviews in Musculoskeletal Medicine. PubMed 40789979
14. Perovic D, et al. (2019). Stable gastric pentadecapeptide BPC 157 can improve the healing course of spinal cord injury and lead to functional recovery in rats. Journal of Orthopaedic Surgery and Research. PubMed 31266512
15. Sikiric P, et al. (1993). A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. Journal of Physiology, Paris. PubMed 8298609
16. Sikiric P, et al. (1997). Pentadecapeptide BPC 157 positively affects both non-steroidal anti-inflammatory agent-induced gastrointestinal lesions and adjuvant arthritis in rats. Journal of Physiology, Paris. PubMed 9403784
17. Staresinic M, et al. (2003). Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. Journal of Orthopaedic Research. PubMed 14554208
18. Staresinic M, et al. (2006). Effective therapy of transected quadriceps muscle in rat: Gastric pentadecapeptide BPC 157. Journal of Orthopaedic Research. PubMed 16609979
19. Tudor M, et al. (2010). Traumatic brain injury in mice and pentadecapeptide BPC 157 effect. Regulatory Peptides. PubMed 19931318
20. Vasireddi N, et al. (2025). Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal. PubMed 40756949
21. Wu H, et al. (2020). Clopidogrel-Induced Gastric Injury in Rats is Attenuated by Stable Gastric Pentadecapeptide BPC 157. Drug Design, Development and Therapy. PubMed 33376304
22. Xu C, et al. (2020). Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regulatory Toxicology and Pharmacology. PubMed 32334036
23. Yildirim AK, et al. (2026). Endothelium-Dependent Nitric Oxide-Mediated Vasorelaxant Effects of BPC 157 in Human Internal Mammary Artery. Journal of Clinical Medicine. PubMed 42123221
24. Zhang J, et al. (2026). BPC157 drives angiogenesis through FBXO22-dependent stabilization of BACH1. Cell Communication and Signaling. PubMed 41606641